Veracyte, Inc. , a leading cancer diagnostics company, today announced that new data presented at the 2025 ASCO Genitourinary Cancers Symposium (ASCO GU) demonstrate the performance and clinical ...

Intelligently searches through manuals, troubleshooting guides, and service history to answer technician questions and proactively recommend service resolutions ...

Deutsche Bank analyst David Hoang initiated coverage of Sarepta (SRPT) with a Hold rating and $136 price target Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover ...

CAMBRIDGE, Mass., February 14, 2025--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, announced today that it has closed on a $600 million senior secured revolving credit facility ...

Arrowhead (ARWR) announced that the global licensing and collaboration agreement with Sarepta Therapeutics (SRPT) announced on November 26, 2024, has now closed. Closing of the transaction was ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2024 financial results after the Nasdaq Global Market ...

Read Our Latest Stock Report on SRPT Sarepta Therapeutics Stock Down 0.3 % Shares of NASDAQ SRPT opened at $111.82 on Thursday. Sarepta Therapeutics has a 1 year low of $102.15 and a 1 year high ...

Erste Asset Management GmbH bought a new position in Sarepta Therapeutics during the 3rd quarter valued at about $79,425,000. Janus Henderson Group PLC boosted its holdings in shares of Sarepta ...